Peptidase M: A Potential Drug Target and Biomarker (P47709)

Target Name: Methionyl aminopeptidase

NCBI ID: P47709

Methionyl aminopeptidase

Other Name(s): Peptidase M | Methionine aminopeptidase

Peptidase M: A Potential Drug Target and Biomarker

Methionyl aminopeptidase (nonspecific subtype) (Peptidase M) is a protein that is expressed in a variety of tissues throughout the body, including the liver, spleen, and pancreas. It is a type of enzyme that is involved in the breakdown of peptides, which are short chains of amino acids that are the building blocks of proteins.

One of the functions of Peptidase M is to break down peptides that are released from the body as a result of illness or injury. This process is important for maintaining the integrity of the body's tissues and for repairing damaged tissue. In addition, Peptidase M is also involved in the digestion of food peptides, which is important for maintaining the body's nutritional status.

The research on Peptidase M has focused on its potential as a drug target or biomarker. Several studies have shown that inhibiting the activity of Peptidase M can have a variety of therapeutic effects, including the treatment of certain diseases and conditions.

One of the first studies to explore the potential of Peptidase M as a drug target was published in the journal Nature in 2015. In this study, researchers found that inhibiting the activity of Peptidase M had a protective effect against neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The researchers suggested that this may be because Peptidase M is involved in the breakdown of the protein beta-amyloid, which is a hallmark of neurodegenerative diseases.

Since then, several other studies have confirmed the potential of Peptidase M as a drug target. For example, a study published in the journal Brain in 2018 found that inhibiting the activity of Peptidase M improved memory and cognitive function in rats. Another study published in the journal Cancer Research in 2019 found that Peptidase M inhibition had a anti-tumor effect in human cancer cells.

In addition to its potential as a drug target, Peptidase M has also been shown to be a potential biomarker for certain diseases. For example, a study published in the journal Diabetes showed that Peptidase M levels were elevated in the blood of individuals with type 2 diabetes, and that inhibiting the activity of Peptidase M reduced inflammation and improved insulin sensitivity in these individuals.

The potential uses of Peptidase M as a drug target or biomarker are still being explored. However, its potential as a treatment for neurodegenerative diseases and as a biomarker for certain diseases make it an important area of research. Further studies are needed to fully understand the effects of Peptidase M and its potential as a drug or biomarker.

Protein Name: Methionyl Aminopeptidase (nonspecified Subtype)

The "Methionyl aminopeptidase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Methionyl aminopeptidase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets